Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Ayala Asset Purchase Agreement Common Stock	Ayala Asset Purchase Agreement Additional Paid-in Capital	Ayala Asset Purchase Agreement	Zentalis Asset Purchase Agreement Common Stock	Zentalis Asset Purchase Agreement Additional Paid-in Capital	Zentalis Asset Purchase Agreement	License agreement with Zentalis Pharmaceuticals, Inc Common Stock	License agreement with Zentalis Pharmaceuticals, Inc Additional Paid-in Capital	License agreement with Zentalis Pharmaceuticals, Inc	BMS License Agreement Common Stock	BMS License Agreement Additional Paid-in Capital	BMS License Agreement	ATM Common Stock	ATM Additional Paid-in Capital	ATM	PIPE Funding Common Stock	PIPE Funding Additional Paid-in Capital	PIPE Funding	Public offering Common Stock	Public offering Additional Paid-in Capital	Public offering	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Total
Balance at Dec. 31, 2022																						$ 1	$ 132,653		$ (116,001)	$ 16,653
Balance (in shares) at Dec. 31, 2022																						12,128,843
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense																							6,153			6,153
Issuance of common stock														$ 34	$ 34	$ 2	$ 116,001	$ 116,003					221			221
Issuance of common stock (in shares)													5,925			21,690,871						55,250
Issuance of common stock and stock-based equity awards for Morphimmune merger																						$ 1	87,160			87,161
Issuance of common stock and stock-based equity awards for Morphimmune merger (in shares)																						8,835,710
Vesting of restricted stock awards																							70			70
Vesting of restricted stock awards (in shares)																						12,498
Exercise of stock options																							371			$ 371
Exercise of common stock warrants (in shares)																						522,681				0
Unrealized gain on marketable securities																								$ 22		$ 22
Net loss																									(106,806)	(106,806)
Balance at Dec. 31, 2023																						$ 4	342,663	22	(222,807)	119,882
Balance (in shares) at Dec. 31, 2023																						43,251,778
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense																							15,748			15,748
Issuance of common stock		$ 50,645	$ 50,645		$ 20,990	$ 20,990		$ 23,388	$ 23,388					$ 19,576	$ 19,576				$ 2	$ 215,408	$ 215,410
Issuance of common stock (in shares)	2,175,489			1,805,502			2,298,586			230,415	2,699,000	2,699,000	2,030,431						11,500,000
Exercise of stock options																							2,024			$ 2,024
Exercise of stock options (in shares)																						795,571				769,382
Exercise of common stock warrants																							3,731			$ 3,731
Exercise of common stock warrants (in shares)																						373,057				373,057
Unrealized gain on marketable securities																								35		$ 35
Net loss																									(292,963)	(292,963)
Balance at Dec. 31, 2024																						$ 6	$ 696,872	$ 57	$ (515,770)	$ 181,165
Balance (in shares) at Dec. 31, 2024																						64,460,829